A proof-of-concept trial of methylphenidate in 6-12 children with apraxia of speech

The Murdoch Children’s Research Institute is trialling a new treatment for children with childhood apraxia of speech (CAS). This treatment is the drug methylphenidate (MPH), commonly known as Ritalin. We want to find out whether MPH can help improve the speech and language symptoms of CAS in children aged 6-12 years.

MPH is approved as a treatment for ADHD in children. We want to find out if it is effective for children with CAS.

To be eligible to participate in the trial, children must:

  • have a confirmed diagnosis of CAS
  • be aged 6-12 years
  • be able to complete spoken tasks
  • not have epilepsy, congenital heart disease, severe Tourette Syndrome or severe intellectual disability

The trial will last for 2 months. It will involve only one visit to RCH for an initial health and medical screening. It will also involve four Zoom calls with the study team for speech and language assessments.

If you would like to find out more about the study, please contact the study team: speechtrial@mcri.edu.au

 

Click here to download a copy of the flyer for the trial.

Proudly in partnership with